Inhibitor pusat pemeriksaan imun adalah kelas ubat yang melawan dengan sistem imun badan untuk melawan sel-sel kanser. Walau bagaimanapun, kebanyakan pesakit tidak bertindak balas terhadap terapi ini. Terdapat kelas ubat yang lebih baru yang menyasarkan dua protein yang terlibat dalam menekan tindak balas imun badan terhadap tumor.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from kanser with the molecule M7824. These researchers are also undertaking trials with those suffering from barah pankreas and those infected with HPV.
There are many other trials and experiments being taken to treat and cure cancer more effectively in different research institutes. This drug with a dual approach will be a boon in the rawatan kanser, as with a single molecule, multiple therapies are included.
